SCHEMBL4591255

SCHEMBL4591255

COC(=O)c1cccc(-c2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 4/20 0.65
SUCNR1 Q9BXA5 1/20 0.60
ABL1 P00519 1/20 0.57
SCN9A Q15858 4/20 0.53
SCN2A Q99250 2/20 0.52
EPHB4 P54760 1/20 0.51
TEK Q02763 1/20 0.51
ADORA3 P0DMS8 1/20 0.50
MAPT P10636 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
SCN5A Q14524 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28446016 0.86 SUCNR1 (0.62) SCN10ASUCNR1ABL1SCN9ASCN2A
SCHEMBL25002929 0.85 ADORA3 (0.52) SCN10ASCN9AADORA3MAPTKDM4E
SCHEMBL22940136 0.85 SCN10A (0.61) SCN10ASUCNR1ABL1SCN9ASCN2A
SCHEMBL3134594 0.84 SCN10A (0.60) SCN10ASUCNR1ABL1SCN9A
SCHEMBL25003803 0.84 SUCNR1 (0.67) SCN10ASUCNR1ABL1SCN9ASCN2A
SCHEMBL11297183 0.82 MAPT (0.61) SCN9AMAPT
SCHEMBL24994330 0.82 SCN10A (0.66) SCN10ASUCNR1ABL1SCN9ASCN2A
SCHEMBL364607 0.82 SCN9A (0.64) SCN9AMAPT
SCHEMBL3711274 0.82 MCL1 (0.55) SCN9AMAPTALDH1A1HPGD
SCHEMBL483444 0.81 MAPT (0.56) SCN10ASCN9AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023010192-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 WO disclosed
US-7429605-B2 Phenylpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-30 US disclosed
EP-1912969-A1 PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-23 EP disclosed
WO-2007017169-A1 PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-15 WO disclosed
US-20070032530-A1 Phenylpyridine derivatives HOFFMANN-LA ROCHE INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032530-A1 Phenylpyridine derivatives CYP3A5, QDPR, DPYD SCN10A 1868/4885SUCNR1 748/4885ABL1 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.